Bristol Myers Squibb (US)

Alle Meldungen

26.08

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024

Category: Download PDF Format (opens in new window) New analyses, including presentations on CAMZYOS ® (mavacamten), ELIQUIS ® (apixaban) and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular...

Zur Pressemeldung auf news.bms.com
22.08

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Statement on Oncologic Drugs Advisory Committee (ODAC) Meeting to Discuss PD-L1 Expression Levels in Gastric and Esophageal Cancers

Category: Corporate/Financial News Download PDF Format (opens in new window) The U.S. Food and Drug Administration (FDA) will hold a public meeting of the Oncologic Drugs Advisory Committee (ODAC) on September 26, 2024, to discuss a class-wide...

Zur Pressemeldung auf news.bms.com
21.08

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

Category: Corporate/Financial News Download PDF Format (opens in new window) Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s...

Zur Pressemeldung auf news.bms.com
19.08

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Category: Corporate/Financial News Download PDF Format (opens in new window) Application based on the TRANSCEND FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile Breyanzi also...

Zur Pressemeldung auf news.bms.com
26.07

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Reports Second Quarter Financial Results for 2024

Category: Corporate/Financial News Download PDF Format (opens in new window) Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement Second Quarter Revenues were $12.2 Billion,...

Zur Pressemeldung auf news.bms.com
26.07

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day

Category: Corporate/Financial News Download PDF Format (opens in new window) PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Virtual Targeted Protein Degradation Day...

Zur Pressemeldung auf news.bms.com
19.07

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Category: Corporate/Financial News Download PDF Format (opens in new window) The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice...

Zur Pressemeldung auf news.bms.com
18.07

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Reaches Major Milestone in Environmental Sustainability

Category: CORPORATE-SOCIAL-RESPONSIBILITY Download PDF Format (opens in new window) SBTi validation affirms BMS’ long-standingcommitment to environmental stewardship (PRINCETON, N.J. – July 18, 2024) Bristol Myers Squibb (NYSE: BMY) today...

Zur Pressemeldung auf news.bms.com
21.06

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab

Category: Corporate/Financial News Download PDF Format (opens in new window) Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate noninferior...

Zur Pressemeldung auf news.bms.com
21.06

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Category: Corporate/Financial News Download PDF Format (opens in new window) Approval based on results from the Phase 1/2 KRYSTAL-1 study where KRAZATI in combination with cetuximab showed an objective response rate of 34% in pretreated patients...

Zur Pressemeldung auf news.bms.com

Wem folgen?

SK Rapid
Folgen
Klima- und Energiefonds
Folgen
KTM
Folgen

Mehr anzeigen

Trends

Tesla
Folgen
Black Friday
Folgen
Transit
Folgen
Menschenrechte
Folgen
Aktionstag
Folgen
Advent
Folgen
Tierschutz
Folgen

Mehr anzeigen

uncovr pure news - Die neue Art Presseinhalte zu recherchieren. Mehr Info